Aktienanalyse zu Opus Genetics Inc (IRD)IRDOpus Genetics Inc

Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy. It operates in the Healthcare sector.

Opus Genetics Inc is a good buy right now due to its recent FDA approval for a new eye drop treatment, which is expected to drive future revenue growth. The current price is $3.84, and analysts have set a price target as high as $20, suggesting a potential upside of over 420%. Additionally, the stock has shown a year-to-date change of +81.13%, indicating strong performance despite recent volatility. However, the RSI is currently at 17.549, indicating that the stock is oversold and may rebound. The main risk is the company's significant net losses, with a net income of -65.5 million in Q1 2026, which could impact investor confidence.